Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | KCNA2 | P16389 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383938 | 0.86 | CYP3A4 (0.74) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL6200404 | 0.86 | CYP3A4 (0.74) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Isopimpinellin SCHEMBL498907 | 0.85 | CYP3A4 (1.00) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Isopimpinellin SCHEMBL29568822 | 0.85 | CYP3A4 (1.00) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL20278781 | 0.84 | CYP3A4 (0.80) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL434686 | 0.81 | CYP3A4 (0.80) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL4187228 | 0.81 | CYP3A4 (0.80) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL31542614 | 0.81 | CYP3A4 (0.80) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| SCHEMBL5346577 | 0.80 | CYP3A4 (0.64) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 | |
| Hydrochloric Acid SCHEMBL6196679 | 0.79 | CYP3A4 (0.62) | CYP3A4KDM4ECYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5707808-A | Optical selection and collection of DNA fragments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-01-13 | — | — | US | claimed |
| US-7078389-B2 | Chemically modified oligonucleotide for site-directed mutagenesis | YALE UNIVERSITY (US) | 2006-07-18 | — | — | US | disclosed |
| US-6924373-B2 | comprising a furocoumarin derivative linked to acridinium-9-carboxamide via amide bond at position 9; for chemiluminescent labeling of a nucleic acid | ASIAGEN CORPORATION (TW) | 2005-08-02 | — | — | US | disclosed |
| US-6858742-B2 | DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds | ASIAGEN CORPORATION (TW) | 2005-02-22 | — | — | US | disclosed |
| US-20040219564-A1 | DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds | ASIAGEN CORPORATION (TW) | 2004-11-04 | — | — | US | disclosed |
| US-20040219538-A1 | DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds | ASIAGEN CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20020028922-A1 | Chemically modified oligonucleotide for site-directed mutagenesis | YALE UNIVERSITY | 2002-03-07 | — | — | US | disclosed |
| EP-0862564-A4 | PHOTOACTIVATABLE COMPOUNDS FOR THE PREVENTION OF INTIMAL HYPERPLASIA AND OTHER DISEASES | MIRAVANT SYST INC (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6054449-A | PHOTODYNAMIC THERAPY | MIRAVANT PHARMACEUTICALS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| US-6008211-A | A PHOTODYNAMIC THERAPY USING A FUNCTIONAL FUROCOUMARIN CONJUGATED WITH A PHOTOSENSITIVE BENZOCHLORIN COMPOUND, WHICH CAUSES CYTOSTASIS BUT NOT CYTOLYSIS WHEN BOUND TO A CELL WHEN ACTIVATED WITH LIGHT; TARGET DRUG DELIVERY | PDT PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5616731-A | WITH A FUROCOUMARIN DERIVATIVE BOUND VIA A SPACER; USEFUL IN DETECTING GENE DEFECTS AND INFECTIOUS DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
| WO-1997005127-A1 | PHOTOACTIVATABLE COMPOUNDS FOR THE PREVENTION OF INTIMAL HYPERPLASIA AND OTHER DISEASES | PDT SYSTEMS, INC. (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996039195-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE FOR SITE-DIRECTED MUTAGENESIS | YALE UNIVERSITY (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0705270-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE FOR SITE-DIRECTED MUTAGENESIS | YALE UNIVERSITY (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995001364-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE FOR SITE-DIRECTED MUTAGENESIS | YALE UNIVERSITY (US) | 1995-01-12 | — | — | WO | disclosed |
| WO-1993010266-A1 | DEVICE AND METHOD FOR DETECTION OF COMPOUNDS WHICH INTERCALATE WITH NUCLEIC ACIDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1993-05-27 | — | — | WO | disclosed |
| EP-0425563-A4 | PROCESS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES | — | 1992-06-10 | — | — | EP | disclosed |
| EP-0425563-A1 | PROCESS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES. | SEGEV DIAGNOSTICS INC (US) | 1991-05-08 | — | — | EP | disclosed |
| WO-1990001069-A1 | PROCESS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES | SEGEV DIAGNOSTICS, INC. (US) | 1990-02-08 | — | — | WO | disclosed |
| EP-0187332-B1 | PHOTOCHEMICAL METHOD OF LABELLING NUCLEIC ACIDS FOR DETECTION IN HYBRIDIZATION ASSAYS | MOLECULAR DIAGNOSTICS, INC. (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219538-A1 | DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds | DNMT1, ACR, DNMT3A | CYP3A4 125/4885KDM4E 957/4885CYP1A2 355/4885 |
| US-20040219564-A1 | DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds | DNMT1, ACR, DNMT3A | CYP3A4 125/4885KDM4E 957/4885CYP1A2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.